StockData
LB Pharmaceuticals Inc logo

LB Pharmaceuticals Inc (LBRX) stock

LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$40.06−0.24 (-0.60%)

Close on Nov 18, 2026Market cap $1.29BP/E –Yield –

LB Pharmaceuticals net income

Net income is the profit left for shareholders after every expense, interest and tax.

LB Pharmaceuticals's net income for the twelve months ending Jun 30, 2026 was -$85.69M. For fiscal 2025 it was -$25.21M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$25.21M–
FY2024Dec 31, 2024-$63.10M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$51.60M–
Q1 FY2026Mar 31, 2026-$19.05M–
Q4 FY2025Dec 31, 2025-$11.47M–
Q3 FY2025Sep 30, 2025-$3.56M–
Q2 FY2025Jun 30, 2025-$4.87M–
Q1 FY2025Mar 31, 2025-$5.31M–
Q4 FY2024Dec 31, 2024-$5.07M–
Q3 FY2024Sep 30, 2024-$14.18M–
Q2 FY2024Jun 30, 2024-$27.63M–
Q1 FY2024Mar 31, 2024-$16.22M–

More LB Pharmaceuticals figures

See a number that looks wrong?